Pàgina inicial > Resultats de la cerca: Baron, Frédéric
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 4 registres trobats en 0.02 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
12 p, 804.5 KB RIC versus MAC UCBT in adults with AML : A report from Eurocord, the ALWP and the CTIWP of the EBMT / Baron, Frédéric (University of Liege) ; Ruggeri, Annalisa (Hôpital Saint-Antoine (Paris, França)) ; Beohou, Eric (Hôpital Saint-Antoine (Paris, França)) ; Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ; Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ; Milpied, Noel (University of Bordeaux) ; Michallet, Mauricette (Centre Hospitalier de Lyon Sud) ; Bacigalupo, Andrea (Ospedale San Martino) ; Blaise, Didier (Aix-Marseille Université) ; Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ; Socié, Gérard (Hospital Saint-Louis) ; Cornelissen, Jan J. (Erasmus Medical Center-Daniel den Hoed Cancer Center) ; Schmid, Christoph (University of Munich) ; Giebel, Sebastian (Gliwice Branch) ; Gorin, Norbert-Claude (Hospital Saint Antoine) ; Esteve, Jordi (Hematology. Hospital Clinic) ; Ciceri, Fabio (Ospedale San Raffaele) ; Savani, Bipin N. (Vanderbilt University Medical Center) ; Mohty, Mohamad (UMRs 938) ; Gluckman, Eliane (Centre Scientifique de Monaco) ; Nagler, Arnon (The Chaim Sheba Medical Center) ; Universitat Autònoma de Barcelona
Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. [...]
2016 - 10.18632/oncotarget.9599
Oncotarget, Vol. 7 Núm. 28 (2016) , p. 43027-43038  
Registre complet - Creative Commons
2.
10 p, 786.4 KB Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation : An EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine / Giannotti, Federica (Saint-Antoine Hospital) ; Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ; Shouval, Roni (Chaim Sheba Medical Center (Israel)) ; Sanz, Jaime (Instituto de Salud Carlos III) ; Arcese, William (Rome Transplant Network tor Vergatä) ; Angelucci, Emanuele (Ospedale Policlinico San Martino) ; Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarone, Stella (Ospedale Civile) ; Benedetto, Bruno (S.S.C.V.D Trapianto di Cellule Staminali A.O.U Citta della Salute e della Scienza di Torino) ; Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII) ; Saccardi, Riccardo (Azienda Ospedaliera Universitaria Careggi) ; Blaise, Didier (Institut Paoli Calmettes) ; Carella, Michele Angelo (IRCCS) ; Rocha, Vanderson (Universidade de São Paulo) ; Baron, Frederic (University of Liege) ; Mohty, Mohamad (Hospital Saint- Antoine) ; Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ; Nagler, Arnon (Tel-Aviv University) ; Universitat Autònoma de Barcelona
Thiotepa-busulfan-fludarabine (TBF) is a widely used conditioning regimen in single umbilical cord blood transplantation (SUCBT). More recently, it was introduced in the setting of non-T cell depleted haploidentical stem cell transplantation (NTD-Haplo). [...]
2018 - 10.1186/s13045-018-0655-8
Journal of hematology & oncology, Vol. 11 Núm. 1 (30 2018) , p. 110  
Registre complet - Creative Commons
3.
11 p, 572.5 KB Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group / Mohty, Mohamad (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ; Malard, F. (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ; Abecasis, Manuel (Instituto Portugues de Oncologia) ; Aerts, E. (University Hospital Zurich (Suïssa)) ; Alaskar, A. S. (Department of Oncology. King Abdulaziz Medical City. King Abdullah International Medical Research Center. King Saud Bin Abdulaziz University for Health Sciences. Ministry of National Guard Health Affairs) ; Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre) ; Arat, Mutlu (HSCT Unit. Sisli Florence Nightingale Hospital) ; Bader, Peter (Division for Stem Cell Transplantation and Immunology. Department for Children and Adolescents. University Hospital. Goethe University) ; Baron, Frederic (CHU and University of Liege) ; Basak, G. (Medical University of Warsaw) ; Bazarbachi, A. (American University of Beirut. Department of Internal Medicine) ; Blaise, Didier (Transplant and Cellular Immunotherapy Program. Department of Hematology. Aix-Marseille Univ. Inserm. CNRS. Institut Paoli-Calmettes. CRCM) ; Ciceri, Fabio (Hematology and Bone Marrow Transplantation Unit. IRCCS Ospedale San Raffaele. University Vita-Salute) ; Corbacioglu, Selim (Department of Pediatric Hematology. Oncology and Stem Cell Transplantation. University of Regensburg) ; Dalle, J. H. (Department of Hematology and Immunology. Hospital Robert Debre. Paris 7-Paris Diderot University) ; Dignan, F. (Department of Clinical Haematology. Central Manchester Foundation Trust) ; Fukuda, T. (HSCT Division. National Cancer Center Hospital) ; Huynh, A. (Institut Universitaire du Cancer Toulouse-Oncopole) ; Kuball, J. (Department of Haematology. University Medical Centre) ; Lachance, S. (Department of Hematology and Stem Cell Transplant Program. Hôpital Maisonneuve-Rosemont. University of Montreal) ; Lazarus, H. (Case Western Reserve University) ; Masszi, T. (St László Hospital (Hongria)) ; Michallet, M. (Hematology Department. Groupement Hospitalier Sud. Hospices Civils de Lyon. Université Claude Bernard Lyon EST) ; Nagler, Arnon (Hematology and Bone Marrow Transplantation. Chaim Sheba Medical Center) ; NiChonghaile, M. (Trinity College Dublin) ; Okamoto, S. (Division of Hematology. Department of Medicine. Keio University School of Medicine) ; Pagliuca, A. (King's College Hospital NHS Foundation Trust) ; Peters, C. (Department of Pediatrics. St. Anna Kinderspital) ; Petersen, F. B. (LDS Hospital) ; Richardson, Paul G.. (Division of Hematology. Mayo Clinic) ; Ruutu, T. (Helsinki University Hospital (Finlàndia)) ; Saber, Wael (Center for International Blood and Marrow Transplant Research. Medical College of Wisconsin) ; Savani, B. N. (Hematology and Stem Cell Transplantation Section. Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center and Veterans Affairs Medical Center) ; Soiffer, R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Division of Hematologic Malignancies) ; Styczynski, Jan (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum UMK) ; Wallhult, E. (Sahlgrenska University Hospital (Suècia)) ; Yakoub-Agha, Ibrahim (CHU de Lille. LIRIC INSERM U995. Université de Lille2) ; Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2020 - 10.1038/s41409-019-0705-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 485-495  
Registre complet - Creative Commons
4.
11 p, 858.6 KB Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation / Baron, Frederic (Université de Liège (Bèlgica)) ; Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ; Ruggeri, Annalisa (Hôpital Saint-Louis (Paris, França)) ; Mohty, Mohamad (Hôpital Saint-Antoine (Paris, França)) ; Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ; Milpied, Noel (Hôpital Haut Léveque (Pessac, França)) ; Bacigalupo, Andrea (Ospedale Sant Martino (Genova, Itàlia)) ; Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII (Bergamo, Itàlia)) ; Bonifazi, Francesca (Policlinico Sant'Orsola-Malpighi (Bologna, Itàlia)) ; Bosi, Alberto (Azienda Ospedaliero Universitaria Careggi (Firenze, Itàlia)) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Yakoub-Agha, Ibrahim (Hôpital Claude Huriez (Lille, França)) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gluckman, Eliane (Hôpital Saint-Louis (Paris, França)) ; Nagler, Arnon (Sheba Medical Center (Ramat Gran, Israel)) ; Universitat Autònoma de Barcelona
BACKGROUND: In the setting of allogeneic human leukocyte antigen (HLA)-matched bone marrow transplantation, transplanting male patients with grafts from female donors has been associated with a higher incidence of graft-versus-host disease (GVHD) and of nonrelapse mortality (NRM). [...]
2015 - 10.1186/s13045-015-0207-4
Journal of hematology & oncology, Vol. 8 Núm. 107 (october 2015)  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 Baron, F.
6 Baron, Frederic
1 Barón, Francisco
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem